News
PULM
1.987
-4.93%
-0.103
Weekly Report: what happened at PULM last week (0408-0412)?
Weekly Report · 3d ago
Weekly Report: what happened at PULM last week (0401-0405)?
Weekly Report · 04/08 09:46
Weekly Report: what happened at PULM last week (0325-0329)?
Weekly Report · 04/01 09:45
Pulmatrix Q4 EPS $(0.57) Beats $(1.04) Estimate, Sales $2.20M Beat $1.77M Estimate
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $0.57 per share. The company reported quarterly sales of $2.20 million. Pulmatrix beat the analyst consensus estimate of $1.77 million by 24.41 percent.
Benzinga · 03/29 03:27
Pulmatrix GAAP EPS of -$3.87, revenue of $7.3M
Seeking Alpha · 03/28 18:50
Press Release: Pulmatrix Announces Year-End and -2-
Pulmatrix is a clinical-stage biopharmaceutical company focused on the development of novel inhaled therapeutic products. Pulmatrix's product pipeline includes treatments for central nervous system disorders and serious lung diseases. The company's net loss for the quarter was $18,836.
Dow Jones · 03/28 13:05
Press Release: Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
Pulmatrix Announces Year-End and Q4 2023 financial results and Provides Corporate Update. $19.2 million cash and cash equivalents provide projected cash runway into Q1 2026. Pulmatrix is a clinical-stage company developing inhaled therapies to address serious central nervous system and pulmonary disease. The company has wind down of the PUR1900 Phase 2b study.
Dow Jones · 03/28 13:05
Weekly Report: what happened at PULM last week (0318-0322)?
Weekly Report · 03/25 09:47
Weekly Report: what happened at PULM last week (0311-0315)?
Weekly Report · 03/18 09:46
Pulmatrix Shifts to Outsourced CMO Model, Terminates Executive
Pulmatrix terminated its Chief Medical Officer, Dr. Margaret Wasilewski, as part of a move to an outsourced, part-time CMO model. The decision was not due to any disagreements on company operations or practices. PULM will receive severance benefits.
TipRanks · 03/13 10:12
Weekly Report: what happened at PULM last week (0304-0308)?
Weekly Report · 03/11 09:45
Pulmatrix to Present at Investor Conferences, Limits Updates
TipRanks · 03/04 21:24
Weekly Report: what happened at PULM last week (0226-0301)?
Weekly Report · 03/04 09:46
Weekly Report: what happened at PULM last week (0219-0223)?
Weekly Report · 02/26 09:50
Weekly Report: what happened at PULM last week (0212-0216)?
Weekly Report · 02/19 09:50
Weekly Report: what happened at PULM last week (0205-0209)?
Weekly Report · 02/12 09:46
Weekly Report: what happened at PULM last week (0129-0202)?
Weekly Report · 02/05 09:50
Weekly Report: what happened at PULM last week (0122-0126)?
Weekly Report · 01/29 09:46
Weekly Report: what happened at PULM last week (0115-0119)?
Weekly Report · 01/22 09:48
Weekly Report: what happened at PULM last week (0108-0112)?
Weekly Report · 01/15 09:46
More
Webull provides a variety of real-time PULM stock news. You can receive the latest news about Pulmatrix through multiple platforms. This information may help you make smarter investment decisions.
About PULM
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as acute migraine and serious lung diseases, such as chronic obstructive pulmonary disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). The Company’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes. The Company’s therapeutic candidates include PUR3100, PUR1800, and PUR1900. PUR3100 is the iSPERSE formulation of dihydroergotamine (DHE), for the treatment of acute migraine.